Evidence map›Paper›PMID 40778996›Full record

ArticleDiscover oncology2025

Identification of potential molecular targets of luteolin in the treatment of hepatocellular carcinoma based on network pharmacology and transcriptome sequencing technology.

Yunqi Han, Huijun Wu, Xin Zhang, Wei Lv, Yang Xiong, Xinyuan Tian, Yunfeng Xiao, Hongwei Cui

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yunqi Han *Inner Mongolia Autonomous Region Fourth Hospital (Chest Hospital), Hohhot, 010080, China.
Huijun Wu *Department of Hepatobiliary Surgery, People's Hospital of Inner Mongolia, Hohhot, 010017, China.
Xin Zhang *Department of Pharmacy, Inner Mongolia Medical University, Hohhot, 010110, China.
Wei LvDepartment of Pharmacy, Inner Mongolia Medical University, Hohhot, 010110, China.
Yang XiongDepartment of Hepatobiliary Surgery, Ordos Central Hospital, Ordos, 017000, China.
Xinyuan TianPeking University cancer Hospital Inner Mongolia Hospital (Inner Mongolia medical university affiliated tumor hospitalï), Hohhot, 010050, China.
Yunfeng XiaoDepartment of Pharmacy, Inner Mongolia Medical University, Hohhot, 010110, China. xiaoyunfeng0472@126.com.
Hongwei CuiPeking University cancer Hospital Inner Mongolia Hospital (Inner Mongolia medical university affiliated tumor hospitalï), Hohhot, 010050, China. cuihw2001423@163.com.

Funding

Capital Region Public Hospital High Level, clinical specialty construction project science and Technology Project 2023SGGZ107Inner Mongolia Archives Science and Technology Project 2022-30Inner Mongolia Medical University Zhiyuan Talent Program (Good Learning Talent Program) ZY0202031Inner Mongolia Mongolian Medicine Collaborative Innovation Center Scientific Research Project MYYXTPY202208Inner Mongolia Natural Science Foundation General Project 2023MS08032Medical Health Science and Technology Program of Inner Mongolia Health Commission 202202378Young Talents of Science and Technology in Universities of Inner Mongolia Autonomous Region NJYT23050
6 · The paper itself

Abstract

objectiveThis study aims to identify potential target genes of luteolin (LUT) for treating hepatocellular carcinoma (HCC) through integrated in vitro experiments, network pharmacology, bioinformatics, and transcriptome sequencing (RNA-seq).

methodsPotential LUT-associated therapeutic targets for HCC were predicted using network pharmacology. The anti-HCC effects of LUT were evaluated in vitro by assessing its impact on SMMC-7721 and HepG2 cell viability, apoptosis, migration, and invasion. Transcriptome sequencing was performed to identify differentially expressed genes (DEGs) in LUT-treated HepG2 cells, followed by bioinformatics analyses to validate hub targets and their associated pathways.

resultNetwork pharmacology predicted 100 potential protein targets of LUT for HCC treatment, implicating pathways related to inflammation, cell migration, cell cycle regulation, and apoptosis, including the HIF-1α signaling axis. In vitro experiments demonstrated that LUT (40, 60, and 90 µmol·L

conclusionLLUT suppresses HCC progression by inhibiting proliferation, regulating cell cycle and apoptosis, and blocking invasion and migration. Its therapeutic mechanisms likely involve targeting MMP9 and modulating the HIF-1α signaling pathway.

Indexed as

Hepatocellular carcinomaLuteolinNetwork pharmacologySignaling pathwayTranscriptomics

Identifiers

PMID40778996
PMCPMC12764707

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.